ArticleGastro hep advances2025
Increased Risk of Post-Acute Sequalae of COVID-19 in Patients With Immune-Mediated Inflammatory Diseases.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Dysregulation of the immune system and chronic inflammation, the primary drivers of post-acute sequalae of corona virus disease 2019 (COVID-19) (PASC), are at the heart of immune-mediated inflammatory disease (IMID) pathology. As PASC remains underexplored in IMID patients, we explored the risk of PASC in patients with IMIDs including spondylarthritis (SpA), rheumatoid arthritis (RA), hidradenitis suppurativa, ulcerative colitis, Crohn's disease and psoriasis compared to a matched non-IMID population. Methods: In this cohort study, all individuals with a recorded positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test (January 2020 to January 2022) were identified from the Danish national registers. Cox regression was used to compare COVID-positive IMID persons with matched COVID-positive non-IMID ones. Subgroup analysis by COVID-related hospitalization, COVID vaccination, IMID medication, and stratification analysis by age, sex, and SARS-CoV-2 variant were carried out. Results: A total of 753 PASC cases were reported among 25,889 IMID and 51,778 matched individuals. The median age and follow-up time were 48 years (interquartile range: 35-61) and 7.7 months (interquartile range: 7.1-16.1), respectively, and 56% were women. An increased risk of PASC was seen in the IMID group as a whole compared to the non-IMID group (hazard ratio (HR): 1.64, 95% confidence interval (CI): 1.42-1.89), and for SpA (HR: 2.05, 95% CI: 1.30-3.22), RA (HR: 1.90, 95% CI: 1.38-2.61), and psoriasis (HR: 1.62, 95% CI: 1.31-2.01) individually. The risk of PASC remained higher among hospitalized and vaccinated IMID patients. Conclusion: This study showed an increased risk of PASC in individuals with an IMID and in SpA, RA, and psoriasis individually. Results indicate chronic impact of early SARS-CoV-2 infection on IMID patients following acute COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.